西点药业：左氧氟沙星滴眼液获药品注册证书

Core Viewpoint - West Point Pharmaceutical (301130) has received the Drug Registration Certificate from the National Medical Products Administration for its Levofloxacin Eye Drops, which will enhance the company's product line and market competitiveness, positively impacting future performance [1] Company Summary - The newly approved drug is intended for the treatment of infectious diseases caused by sensitive bacteria, including blepharitis, meibomian gland dysfunction, dacryocystitis, conjunctivitis, meibomianitis, and keratitis [1] - The approval of this product is expected to contribute to the company's revenue growth and overall market position [1]